Myelin-specific T-cells as biomarker in multiple sclerosis patients treated with natalizumab

Barbara Willekens, Neurologist, and postdoc researcher, presents a prospective longitudinal cohort study in patients with RRMS treated with natalizumab. The study analyzes if myelin-specific T-cells in blood can be used as biomarker to assess and predict immunomodulatory effect of antigen specific treatment in patients. In conclusion, measured T-cell reactivity was not stable over time, hence future studies measuring other cytokine signatures may be next step. Read more: P609 Longitudinal analysis of autoreactive T cells in a cohort of multiple sclerosis patients treated with natalizumab